Why the study?
Does adriamycin induce objective response or remission in patients with advanced neoplastic disease?
Does adriamycin induce objective response or remission in patients with advanced neoplastic disease?
Adriamycin demonstrates antitumor activity in advanced neoplastic diseases, supporting its exploration earlier in the therapeutic course despite significant hematologic and gastrointestinal toxicities.
Supports exploration in refractory neoplasms; leaves open optimal sequencing and toxicity management in prospective trials.
Adriamycin is a hydroxymethyl analog of daunorubicin with antitumor effect in man. We have studied 86 patients: 44 with acute leukemia (27 children and 17 adults), and 42 solid tumors (20 children and 22 adults). Objective response was seen in 1 of 1 Wilms' tumor, 5 of 8 neuroblastomas, 2 of 3 Ewing's sarcomas, 4 of 5 reticulum cell sarcomas; 3 of 9 osteogenic sarcomas, 3 of 6 bronchogenic carcinomas, and 1 of 1 lymphosarcoma. Complete remission (M-1 marrow) was seen in 1 of 14 acute myelocytic leukemias. Of 30 acute lymphocytic leukemias, 5 had complete and 1 had partial remission. Responses lasted from 0.25 months to 10+ months with a median of 3 months. Except for patients with osteogenic sarcomas and bronchogenic carcinomas, all received prior chemotherapy. Major toxicity of adriamycin included granulocytopenia, lymphocytopenia, thrombocytopenia, anemia, marrow hypoplasia, stomatitis, vomiting, and alopecia. Activity of adriamycin in these patients with advanced disease supports its exploration in patients earlier in their therapeutic course.
No takes yet. Share an insight, caveat, or question.
Wang et al. (1971) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Cancer